SG Americas Securities LLC Boosts Stake in Poseida Therapeutics, Inc. (NASDAQ:PSTX)

SG Americas Securities LLC grew its stake in shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) by 25.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 30,623 shares of the company’s stock after buying an additional 6,206 shares during the period. SG Americas Securities LLC’s holdings in Poseida Therapeutics were worth $294,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the stock. State Street Corp lifted its stake in shares of Poseida Therapeutics by 2.3% during the 3rd quarter. State Street Corp now owns 1,710,565 shares of the company’s stock worth $4,892,000 after purchasing an additional 38,770 shares during the period. Dimensional Fund Advisors LP increased its stake in Poseida Therapeutics by 1.6% in the second quarter. Dimensional Fund Advisors LP now owns 599,812 shares of the company’s stock valued at $1,749,000 after purchasing an additional 9,672 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in Poseida Therapeutics by 3.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 567,063 shares of the company’s stock worth $1,622,000 after buying an additional 21,255 shares during the period. Trium Capital LLP acquired a new stake in Poseida Therapeutics in the 4th quarter worth about $3,710,000. Finally, Connor Clark & Lunn Investment Management Ltd. grew its holdings in Poseida Therapeutics by 62.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 359,197 shares of the company’s stock valued at $1,027,000 after buying an additional 138,510 shares during the period. 46.87% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on PSTX. BTIG Research reiterated a “neutral” rating on shares of Poseida Therapeutics in a report on Tuesday, November 26th. Cantor Fitzgerald downgraded shares of Poseida Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 26th. Piper Sandler cut shares of Poseida Therapeutics from an “overweight” rating to a “neutral” rating and set a $10.00 price objective for the company. in a research note on Monday, December 2nd. William Blair reaffirmed a “market perform” rating on shares of Poseida Therapeutics in a research report on Tuesday, November 26th. Finally, HC Wainwright reiterated a “neutral” rating and issued a $9.00 target price (down previously from $20.00) on shares of Poseida Therapeutics in a report on Tuesday, November 26th. Five investment analysts have rated the stock with a hold rating, Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $9.50.

Insiders Place Their Bets

In other news, Chairman Mark J. Gergen sold 30,000 shares of Poseida Therapeutics stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $9.46, for a total transaction of $283,800.00. Following the sale, the chairman now owns 651,291 shares in the company, valued at $6,161,212.86. This trade represents a 4.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.90% of the stock is currently owned by insiders.

Poseida Therapeutics Stock Performance

Shares of PSTX stock opened at $9.50 on Thursday. Poseida Therapeutics, Inc. has a fifty-two week low of $1.87 and a fifty-two week high of $9.67. The firm’s 50 day moving average price is $9.47 and its two-hundred day moving average price is $5.26. The stock has a market cap of $928.85 million, a price-to-earnings ratio of -15.08 and a beta of 1.63. The company has a quick ratio of 3.20, a current ratio of 3.20 and a debt-to-equity ratio of 0.68.

Poseida Therapeutics (NASDAQ:PSTX) last posted its earnings results on Thursday, November 7th. The company reported $0.21 earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.63. Poseida Therapeutics had a negative net margin of 40.28% and a negative return on equity of 72.26%. The business had revenue of $71.75 million for the quarter, compared to analyst estimates of $15.00 million. On average, analysts anticipate that Poseida Therapeutics, Inc. will post -1.02 EPS for the current year.

About Poseida Therapeutics

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.